

Syncope: What to Do When the Lights Go Out?

Robert Dachs, MD, FAAFP
Director of Graduate Medical Education
Department of Emergency Medicine, Ellis Hospital
Clinical Associate Professor
Ellis Hospital Family Residency Program
Albany Medical College
Schenectady, NY



1

Disclosure

I have no financial interests or relationships to disclose.



2

Learning Objectives

Upon completion, the participant will be able to:

1. Conduct an appropriate diagnostic evaluation for the patient with syncope
2. Recognize potentially life-threatening EKG's that are associated with syncope
3. Describe patients with syncope that are "high risk" for subsequent fatal arrhythmia events.
4. Be familiar with the 2017 AHA/ACC guideline for syncope



3

Your Patient *"Passed Out"...* Your Differential Diagnosis Is:

CV causes

- **Autonomic**
 - Carotid sinus syncope
 - Cough
 - Defecation
 - Excessive vagal tone (athletes, adolescents)
 - Micturition
 - Postprandial
 - Sneeze
 - Swallow
 - Valsalva

Non-CV causes

- **Metabolic**
 - Alcoholism
 - Carbon monoxide
 - Drug-induced
 - Hyperventilation
 - Hypoglycemia
 - Hypothyroid
 - Hypoxia/asphyxiation
 - pheochromocytoma

4

Your Patient *"Passed Out"* ... Your Differential Diagnosis Is:

CV causes

- **Orthostatic hypotension**
 - Adrenal insufficiency
 - Autonomic insufficiency
 - CNS dz, alcoholism, DM
 - Dehydration
 - Drugs
 - Antihypertensives
 - Drugs of abuse
 - Vasodilators
 - CNS drugs
 - Hemorrhage
 - idiopathic

Non-CV causes

- **CNS**
 - Basilar artery migraine
 - Narcolepsy
 - Seizure
 - Subarachnoid hemorrhage
 - Subclavian steal
 - Vertebrobasilar insufficiency
 - Increased intracranial pressure

5

Your Patient *"Passed Out"* ... Your Differential Diagnosis Is:

CV causes

- **Obstructive lesions**
 - Aortic dissection
 - Aortic, mitral or pulmonary stenosis
 - Atrial myxoma
 - Cardiac tamponade
 - Congenital heart disease
 - Left ventricular dysfunction
 - Pulmonary embolism
 - Pulmonary hypertension

Non-CV causes

- **Psychiatric**
 - Anxiety disorder
 - Breath-holding spells
 - Conversion reaction
 - Drug-induced
 - Anticonvulsants
 - Antihistamines
 - Antiparkinson drugs
 - Cholinesterase inhibitors
 - TCA
 - Pseudoseizure

6

Your Patient *"Passed Out"*... Your Differential Diagnosis Is:

CV causes

- **Dysrhythmias**
 - Bradyarrhythmia
 - Heart blocks, Sick sinus syndrome,
 - Meds: Beta and Ca-Channel blockers, digoxin, cholinesterase inhibitors
 - Tachyarrhythmias
 - Supraventricular and ventricular
 - Torsades de pointes
 - Drug induced
 - TCA, digoxin, antiarrhythmics
 - Prolonged Q-T syndrome
 - Congenital
 - Drug-induced
 - Myocardial infarction
 - Pacemaker failure, ICD malfunction

7

What Do You Really Want to Know?

- Dangerous etiology vs. Benign etiology

8

“Those who suffer from frequent and strong faints without any manifest cause die suddenly”

Hippocrates (460 - 375 BC)



9

What Do You Really Want to Know?

- Dangerous etiology vs. Benign etiology
- Medical-legal peril vs. None

Admit vs. discharge to home?

10

What Do You Really Want to Know?

- Dangerous etiology vs. Benign etiology
- Medical-legal peril vs. None

Admit vs. discharge to home?

What work-up is needed?

11

Syncope

- Definition *- very useful*
- Pathophysiology *- very useful*
- H & P elements *- that are useful*
- Tests/
Clinical Policies *- that might be useful*
- EKG's *- that are worrisome!*
- The outpatient evaluation

12

Syncope - Definition

- “A brief loss of consciousness associated with an inability to maintain postural tone that spontaneously and completely resolves without medical intervention”

13

Syncope - Definition

- “A **brief** loss of consciousness associated with an inability to maintain postural tone that spontaneously and completely resolves without medical intervention”
- **Brief:** not asleep/intoxicated, not post-ictal

14

Syncope or Too Much to Drink (or Dead)?



15

Syncope - Definition

- “A **brief** loss of consciousness associated with an inability to maintain postural tone that **spontaneously** and completely resolves without medical intervention”
 - **Brief:** not asleep/intoxicated, not post-ictal
 - **Spontaneous:** no intervention needed....
so rarely=> “hypoglycemia”

16

Syncope - Definition

- “A **brief** loss of consciousness associated with an inability to maintain postural tone that **spontaneously** and **completely** resolves without medical intervention”
 - Brief: not asleep/intoxicated, not post-ictal
 - Spontaneous: no intervention needed....
so rarely=> “hypoglycemia”
 - **Completely:** no neurologic deficit, return to baseline

17

Syncope- Pathophysiology

- Global cerebral hypoperfusion

Forget the “TIA” diagnosis/eval

18

Syncope

- Definition - *very useful*
- Pathophysiology - *very useful*
- H & P elements - *that are useful*
- Tests/
Clinical Policies - *that might be useful*
- EKG's - *that are worrisome!*
- The outpatient evaluation

19

Syncope - History

High - risk

- Older age
- (+) CV diagnosis
- (+) CHF
- (+) Family Hx
- No prodrome
- Supine position
- Assoc. with exertion

(think structural outflow obstruction)

Lower - risk

- younger age
- (-) CV diagnosis
- (-) CHF
- (-) Family Hx
- (+) prodrome
- (-) exertion

20

Syncope - History Age Does Matter!!!

- Methods: prospective study, ED pts (+) syncope
- Results: 477 patients, 97% f/u @14 days
 - 80 (18%) patients with “serious event”


<u>AGE</u>	<u># (%) serious outcome</u>	<u>Odds Ratio</u>
< 40	4/141 (3%)	1.0
40-59	15/112 (13%)	2.7
60- 79	30/115 (26%)	3.8
80+	31/109 (28%)	3.9

Note: 63/80 events were noted in ED

Sun, BC, et al. J Am Ger Soc, 2007

21

Incidence Rates of Syncope According to Age and Sex



Soteriades, E. et al. N Engl J Med 2002;347:878-885

22

Syncope - History

High - risk

- Older age ✓
 - (+) CV diagnosis
 - **(+) CHF**
 - (+) Family Hx
 - No prodrome
 - Supine position
 - Assoc. with exertion
- (think structural outflow obstruction)*

Lower - risk

- younger age
- (-) CV diagnosis
- (-) CHF
- (-) Family Hx
- (+) prodrome
- (-) exertion

23

Data to Support Risk Factors

- **Methods:** Retrospective study, Kaiser data, 02-06
 - 22,189 patients with 23,951 syncope episodes
 - 307 deaths in 30 days

- **Results:**

	<u>Hazard Ratio</u>
-CHF: (age 18-59)	14.3
(age 60-79)	3.1
(age 80+)	2.3
-Diabetes	1.5
-Seizure	1.6
-Dementia	1.4

30-day Death rate:

0.2% < 60yrs without CHF, 2.5% all ages with CHF

Derosé SF, et al. Acad Emerg Med 2012

24

Syncope - History

High - risk

- Older age
- (+) CV diagnosis
- **(+) CHF**
- (+) Family Hx
- No prodrome
- Supine position
- Assoc. with exertion

(think structural outflow obstruction)

Lower - risk

- younger age
- (-) CV diagnosis
- (-) CHF
- (-) Family Hx
- (+) prodrome
- (-) exertion

25

Syncope - Step 2 in History The Episode....

Syncope vs. Seizure

- Ask observers
 - Duration
 - Interventions required
 - Seizure activity, tongue biting, incontinence

26

Syncope vs. Seizure

Don't confuse with ***“convulsive syncope”***

- 0.03% of all blood donors
- 12% of all syncope
- Men > women
- Individual variable response to global cerebral hypoperfusion

Lin JT, et al. Ann Neurol 1982 11(5): 525-8.

27

Syncope vs. Seizure

Suggests seizure

- Tongue biting
- Head turning/posturing
- No memory of LOC
- LOC assoc. with stress
- Cyanosis observed
- Limb jerking observed
- Postictal confusion
- Postictal headache

Suggests syncope

- Presyncopal/prodrome
- Warmth before spell
- Remembered LOC
- Prolonged sitting or standing
- Any chest pain
- Palpitations
- Dyspnea

28

Syncope History-

Step 1: Risk Factors

Step 2: The Episode

Step 3: **What Are the Meds?**

- Syncope Clinic, Duke Univ
 - 70 pts - 13% of syncope due to meds

Hanlon, JT, et al. Arch Intern Med, 1990

29

Syncope History

Step 3: **What are the meds?**

- Drugs that cause hypotension
 - Alpha blockers, diuretics
- Drugs that cause bradyarrhythmias
 - B-blockers, Ca⁺ channel blockers,
 - **Alzheimer meds?**
- Drugs that cause prolonged QT

30

Cholinesterase Inhibitors Do Increase Risk of Syncope!!!


- **Methods:** population-based cohort study,
 - Location: Ontario, Canada; 2002-2004
 - Patients with dx: dementia
- **Results:**

	Controls <u>n=61,499</u>	(+) cholinesterase <u>n= 19,803</u>
Hospital visits for syncope		1.76x (1.57-1.98)
Bradycardia		1.69x (1.32-2.15)
Pacer insertion		1.49x (1.12-2.00)
Hip fracture		1.18x (1.04-1.34)

Gill, SS, et al. Arch Intern Med, May 11, 2009

31

Oct 11, 2009 - 85 y/o Near Syncope Meds: Verapamil, Digoxin, Aricept, Exelon Patch



32

Syncope History

Step 3: What are the meds?

- Drugs that cause hypotension
 - Alpha blockers, diuretics
- Drugs that cause bradyarrhythmias
 - B-blockers, Ca⁺ channel blockers,
 - *Alzheimer meds?*
- Drugs that cause prolonged QT

33

Drugs That Can Cause Prolong QTc/Torsades

Antiarrhythmics

- Amiodarone
- Disopyramide
- Sotalol
- Flecainide
- Ibutilide
- Procainamide
- Propafenone
- Quinidine

Anti-anginal

- Ranolazine

Macrolides

- Erythromycin
- Clarithromycin
- Azithromycin**

Quinolones

- Ciprofloxacin
- Gatifloxacin
- Levofloxacin**
- Moxifloxacin

Antifungal

- Fluconazole**
- Itraconazole

TCA's/SSRI's

- Amitriptyline
- Desipramine
- Doxepin
- Fluoxetine
- Imipramine
- Paroxetine
- Sertraline
- Trazodone
- Venlafaxine

Anti-emetic

- ondansetron**
- droperidol**


Antipsychotic

- Droperidol
- Haloperidol
- Pimozide
- Quetiapine**
- Risperidone
- Paliperidone
- Thioridazine
- Chlorpromazine
- Citalopram**

www.crediblemeds.org

34

Azithromycin-induced Polymorphic Ventricular Tachycardia (VT) in a 24-y-old Woman with No Structural Heart Disease and a Normal ECG. The Arrhythmias Resolved with Stopping the Drug



Zhenjiang Yang et al. *Circ Arrhythm Electrophysiol.*
2017;10:e003560



Copyright © American Heart Association, Inc. All rights reserved.

35

Is Azithromycin Associated with Arrhythmia and Death?

Yes

- **Ray WA, et al. NEJM 2012**
Tennessee Medicaid cohort
CV death HR 2.49 (1.38-4.5)
compared to amoxicillin
- **Rao GA, et al. Ann Fam Med 2014**
VA data base
All death HR 1.62 (1.15-2.3)
compared to amoxicillin

No

- **Svanstrom, et al. NEJM 2013**
Danish database
No difference vs. PCN
- **Trifiro G, et al. CMAJ 2017**
European database
No difference vs. Amoxicillin

36

Syncope History- Step 1: Risk Factors Step 2: The Episode

Step 3: What are the meds?

Next--- The Physical Exam But, what is useful?

- Vitals Signs
- Cardiac Exam
- Abdominal Exam
- Neuro Exam

??????????

- *Orthostatics?*
- *Carotid sinus massage?*

37

Orthostatic Hypotension

- Defined: 20mmHg drop in BPsys **standing**
- May indicate:
 - volume depletion
 - Cardiac pump failure
 - Medications
 - Autonomic insufficiency

However, it is present in asymptomatic pts
40% in age >70
23% in age <60

Atkins, D, et al. Am J Med, 1991

38

Orthostatic Hypotension

- Defined: 20mmHg drop in BPsys **standing**

Not to be confused with....

39

Orthostatic Hypotension

- Defined: 20mmHg drop in BPsys **standing**

Not to be confused with....

Postural (orthostatic) tachycardia syndrome (POTS)

- Defined: Increase HR ≥ 30 bpm
 - No orthostatic hypotension
 - Frequent symptoms upon standing (*lightheaded, palpitations, tremulousness, blurred vision, weakness*)
 - **Will feel pre-syncope, but do not pass out**

40

Postural (Orthostatic) Tachycardia Syndrome (POTS)

- Pathophysiology: dysautonomia, ?autoimmune?
- Common: 1-3 million Americans
 - 5-10x more common than orthostatic hypotension
 - Women:Men: 5:1

POTS incidence rises significantly post-COVID-19




(Pixabay)

The incidence rate of postural orthostatic tachycardia syndrome has risen significantly since the COVID-19 pandemic, according to a study in the European Heart Journal -- Quality of Care and Clinical Outcomes. Researchers using TriNetX data found that post-pandemic, the incidence rate increased from 1.42 to 20.3 per 1 million person-years. They emphasized the need to screen for the condition in post-COVID patients. **Full Story:** [Healio](#)


41

Postural (Orthostatic) Tachycardia Syndrome (POTS)



42

Postural (Orthostatic) Tachycardia Syndrome (POTS)



Drug therapy

- ✓ midodrine,
- ✓ ivabradine,
- ✓ bisoprolol,
- ✓ fludrocortisone,
- ✓ droxidopa,
- ✓ desmopressin,
- ✓ propranolol,
- ✓ modafinil,
- ✓ methylphenidate,
- ✓ melatonin

All sample sizes 10-50 subjects.

43

Carotid Sinus Hypersensitivity

- First described by Ibn Sina (Avicenna) 980-1037
- Asystole > 3 sec after 5-10 sec of carotid message **OR** drop of 50mm Hg BPsys
- Suggested as common cause of syncope and falls in the elderly
- Pacing is effective for bradyarrhythmia
Pacing **not** effective for vasodepressive



- **How common is it?**
- **Is it the cause of the syncopal episode?**

44

Carotid Sinus Hypersensitivity

- Methods: 272 pts., age >65, single practice in GB
- Results: (+) CSH in 107 (37%)
 - Pts with (+) hx of syncope, falls, dizziness (n= 192)
41%
 - Pts with no hx of syncope no falls, dizziness (n=80)
35%

Kerr, SRJ, et al. Arch Intern Med, 2006

■ **How common is it?** *Very common, in elderly*

■ **Is it the cause of the syncopal episode?** ???

*The presence of CSH (and orthostatics)
does **not** preclude looking for other causes*

45

Syncope History- Step 1: Risk Factors Step 2: The Episode

Step 3: What are the meds?

**Step 4--- The Physical Exam
But, what's useful?**

- Vitals Signs
- Cardiac Exam
- Abdominal Exam
- Neuro Exam

- Orthostatics
- Carotid sinus massage?

46

Syncope History- Step 1: Risk Factors Step 2: The Episode

Step 3: What are the meds?

Step 4--- The Physical Exam

**Step 5 – the tests....
But which ones?**

Ask the question: “How are you feeling?”

47

Syncope: The Dangerous Causes

- ACS
- Aortic dissection
- PE
- AAA
- Ectopic pregnancy
- GI bleed
- SAH

➤ Routine troponin¹,
➤ R/O MI protocols²,
➤ Head CT³

have low/no yield!

¹Hing, R, et al, 2005

²Link, MS, et al, 2001

³Giglio P, et al, 2005

“Be a sniper, don ’t use a shotgun!!”
A. Mattu

48

Syncope: What Diagnostic Studies Are Needed (to Risk Stratify)? ACEP 2007

- **Answer: EKG only**
 - Note: the yield is < 5%
 - But it is low-cost, non-invasive
 - And can potentially identify life-threatening conditions
- ACC/AHA agree (2006, 2017)
 - ***“Routine and comprehensive testing is not useful”***
(Class III recommendation)
- **All other studies are guided by H & P**

49

ARS Question 1: ACEP (2007) and AHA/ACC (2017) Policies States Which of the Following Tests Should Be Performed in All Patients with Syncope?

- A. EKG
- B. EKG + CBC
- C. EKG + CBC + troponin
- D. EKG + CBC + troponin + head CT
- E. Head CT

50

Same Holds True for Elderly!!

- Methods: 2106 admits for syncope, age > 65
– Yale Med Center, 7/1/02 - 12/31/06, retrospective
- | <u>Test</u> | <u>#(%)</u> | <u>Helped determine etiology</u> |
|------------------|-------------|----------------------------------|
| EKG | 2081 (99%) | 72 (3%) |
| Telemetry | 2001 (95%) | 95 (5%) |
| Cardiac enzymes | 1991 (95%) | 9 (0.5%) |
| Head CT | 1327 (63%) | 7 (0.5%) |
| Echo | 821 (39%) | 13 (2%) |
| Carotid U/S, EEG | | <1% |

Estimated costs nationally =\$6 billion/year

Mendu ML, et al, Arch Intern Med, July 27, 2009

51

Syncope

- Definition - ***very useful***
- Pathophysiology - ***very useful***
- H & P elements - ***that are useful***
- Tests/
Clinical Policies - ***that might be useful***
- EKG's - ***that are worrisome!***
- The outpatient evaluation

52

Syncope and EKG Findings

- **Bradycardias, conduction abnormalities (blocks)**
- Atrial and ventricular tachycardias
- Wolff-Parkinson-White (WPW)
- Prolonged QTc/Long QT syndrome
- Brugada Syndrome
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

53

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, Mobitz 2 and 3rd Degree A-V Block*

* Admit/Cardiology

54

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, **Mobitz 2** and **3rd Degree A-V Block***

- **Bradycardias**, conduction abnormalities (blocks)
 - LBBB:
 - RBBB:
 - Bifascicular blocks
 - Trifascicular blocks



55

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, **Mobitz 2** and **3rd Degree A-V Block***

- **Bradycardias**, conduction abnormalities (blocks)
 - **Sinus node dysfunction (“sick sinus syndrome”)***
*(includes tachycardia-bradycardia syndrome)**

- LBBB
- RBBB
- Bifascicular block
- Trifascicular block



*** Admit/Cardiology**

56

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, Mobitz 2 and 3rd Degree A-V Block*

- **Bradycardias, conduction abnormalities (blocks)**


- Sinus node dysfunction (“sick sinus syndrome”) *(includes tachycardia-bradycardia syndrome)*

- **LBBB: no issue** *(except if new + CP = AMI)**

- **RBBB:**

- **Bifascicular blocks**

- **Trifascicular blocks**



* Admit/Cardiology

57

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, Mobitz 2 and 3rd Degree A-V Block*

- **Bradycardias, conduction abnormalities (blocks)**


- Sinus node dysfunction (“sick sinus syndrome”) *(includes tachycardia-bradycardia syndrome)*

- **LBBB: no issue** *(except if new + CP = AMI)**

- **RBBB: no issue** *(except if ST elev V1,2 = Brugada)**

- **Bifascicular blocks**

- **Trifascicular blocks**



* Admit/Cardiology

58

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, Mobitz 2 and 3rd Degree A-V Block*


- **Bradycardias, conduction abnormalities (blocks)**
 - Sinus node dysfunction (“sick sinus syndrome”) *(includes tachycardia-bradycardia syndrome)*
 - **LBBB: no issue** *(except if new + CP = AMI)**
 - **RBBB: no issue** *(except if ST elev V1 = Brugada)**
 - OR**
 - **Bifascicular blocks = RBBB + L ant. fascicular block***
 - **Trifascicular blocks**

* Admit/Cardiology

59


Syncope and EKG Findings

- **Bradycardias, conduction abnormalities (blocks)**
 - Sinus node dysfunction (“sick sinus syndrome”) *(includes tachycardia-bradycardia syndrome)*
 - **LBBB,**
 - **RBBB**
 - **Bifascicular blocks**
 - **Trifascicular blocks**



60


Bifascicular Blocks



Typical bifascicular block pattern: RBBB combined with LAFB (manifested as LAD)

61

Bifascicular Blocks



RBBB with LAFB

- RBBB pattern in precordial leads with RSR' complex in V1-2
- Prominent LAD indicating LAFB

62


Syncope and EKG Findings

- **Bradycardias, conduction abnormalities (blocks)**
 - Sinus node dysfunction (“sick sinus syndrome”) *(includes tachycardia-bradycardia syndrome)*

- LBBB,
- RBBB


- **Bifascicular blocks**

- **Trifascicular blocks**



63

Bifascicular Blocks



RBBB with LPFB and RAD

64

Bifascicular Blocks: Clinical Significance

- Structural heart disease present (50-80%) and extensive fibrosis of the conducting system.

**** risk of progression to complete heart block**
(with damage to the 3rd fascicle)

➤ **Clinical context is important:**

- Rate of progression to complete heart block is 1-4% per year
- In symptom free patients, these figures are ~1% per year
- *Patients with syncope have a 17% annual risk of progression*
- **Syncope/presyncope in the context of a bifascicular block is an indication for admission and monitoring!!!!**

65

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, **Mobitz 2 and 3rd Degree A-V Block***

- **Bradycardias, conduction abnormalities (blocks)**
 - Sinus node dysfunction (“sick sinus syndrome”)
(includes tachycardia-bradycardia syndrome)
 - **LBBB: no issue** (except if new + CP = AMI)*
 - **RBBB: no issue** (except if ST elev V1 = Brugada)*
 - OR**
 - **Bifascicular blocks = RBBB + L ant. fascicular block***
RBBB + L post. fascicular block*
 - **Trifascicular blocks**

* Admit/Cardiology

66

Syncope and EKG Findings


- **Bradycardias, conduction abnormalities (blocks)**
 - Sinus node dysfunction (“sick sinus syndrome”) *(includes tachycardia-bradycardia syndrome)*

– LBBB

– RBBB

– Bifascicular blocks

– **Trifascicular blocks**




67

Trifascicular Blocks:

1) "True" Trifascicular:

RBBB + LAFB + 3rd AV Block



True Trifascicular Block:

- Right bundle branch block
- Left axis deviation (Left anterior fascicular block)
- Third degree heart block


*** Admit/Cardiology**

68

Trifascicular Blocks:

1) "True" Trifascicular: RBBB + LAFB + 3rd AV Block

2) "Incomplete" Trifascicular: RBBB + LAFB + 1st AV Block



Bifascicular block + first degree AV block


- Right bundle branch block
- Left axis deviation (= left anterior fascicular block)
- First degree AV block

69

Trifascicular Blocks:

1) "True" Trifascicular: RBBB + LAFB + 3rd AV Block

2) "Incomplete" Trifascicular: RBBB + LAFB + 1st AV Block



Bifascicular block + first degree AV block


- Right bundle branch block
- Left axis deviation (= left anterior fascicular block)
- First degree AV block

70

Trifascicular Blocks:

1) "True" Trifascicular: RBBB + LAFB + 3rd AV Block

2) "Incomplete" Trifascicular: RBBB + LAFB + 1st AV Block



Bifascicular block + first degree AV block

- Right bundle branch block
- Left axis deviation (= left anterior fascicular block)
- First degree AV block

71

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, Mobitz 2 and 3rd Degree A-V Block*

- **Bradycardias, conduction abnormalities (blocks)**
 - Sinus node dysfunction ("sick sinus syndrome")*
(includes tachycardia-bradycardia syndrome)*
 - LBBB: **no issue** (except if new + CP = AMI)*
 - RBBB: **no issue** (except if ST elev V1 = Brugada)*
 - OR**
 - **Bifascicular blocks = RBBB + L ant. fascicular block***
RBBB + L post. fascicular block*
 - **Trifascicular blocks***

* Admit/Cardiology

72

Syncope and EKG Findings

- **Bradycardias, conduction abnormalities (blocks)**
- Atrial and ventricular tachycardias
- Wolff-Parkinson-White (WPW)
- Prolonged QTc/Long QT syndrome
- Brugada Syndrome
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

* Admit/Cardiology

73

Syncope and EKG Findings

- Bradycardias, conduction abnormalities (blocks)
- Atrial and ventricular tachycardias
- Wolff-Parkinson-White (WPW)
- Prolonged QTc/Long QT syndrome
- Brugada Syndrome
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

* Admit/Cardiology

74


Long QT Syndrome (LQTS)

- **Acquired**
 - Meds, toxins, electrolyte disturbances, ACS, CNS events, HIV
- **Congenital: Autosomal dominant**
 - Associated with 11 genes, 600 mutations
 - Prevalence: estimates 1/2000-7000
 - Median age of sudden death = 32 years
 - Mortality = 20% in first year after syncope
 - 50% mortality within 5 years

*In series of 31 pts. with LQTS, 64% presented with syncope
40% of the patients were not identified at first presentation!
MacCormick JM, et al. Ann Emerg Med, July 2009*

75


- LQTS: Men > 460msec, Women > 440msec



Bazett Formula

$$QTc = \frac{QT}{[RR]^{0.5}}$$

* In leads II, V5




Rapid Bedside

If QT is < 1/2 of
R-R interval is OK*

*only for HR 60-100

76

Long QT Syndrome



77

Brugada Syndrome

- First described in 1992
- Originally thought to be a disease of men of Southeast Asian descent
 - In Philippines: **“Bangungut”**
“scream followed by sudden death during sleep”
 - In Japan: **“Pokkuri”**
“unexpected sudden death at night”
 - In Thailand: **“Lai Tai”** - “death during sleep”
 - In Laos - one death per 1000 inhabitants!!!

78


Brugada Syndrome

- Now believed to be responsible for 40-60% of patients with “idiopathic V fib”
 - Second only to MVA cause of death in young adults in some countries
- Mutation of SCN5A cardiac Na⁺ channel on Chromosome 3 (“*channelopathy*”)
- Recurrent episodes of polymorphic V tach

79

Brugada Syndrome: EKG

- **RBBB** with ST elevation V1-3




Type I -
“coved-shaped” ST
*is diagnostic

Type II -
“concave-shaped” ST
*is non-diagnostic,
But suggests dx in
appropriate patient


80

Brugada Syndrome: EKG




- Look at V1- 3
- Type I

81




82



83

Brugada Syndrome: EKG


- Type II - incomplete RBBB; “concave-shaped” ST, V1-3



Note “saddleback” in V2


84

30 y/o AA Female, Chest Tightness, Palpitations, Near-syncope. Previous Hx of Previous Syncopal Episodes



85

9 Years Earlier...



Courtesy A. Mattu, Univ Maryland.

86

Hypertrophic Cardiomyopathy (HCM)

- First described in mid-19th century
- Previous names:
 - Hypertrophic obstructive cardiomyopathy (HOCM)
 - Idiopathic hypertrophic subaortic stenosis (IHSS)
- Characteristics:
 - Thickened myocardium
 - without ventricular dilation
 - absence of conditions that result in hypertrophy (HTN, Aortic stenosis)
- Incidence: approx. 1 in 500 persons
- Annual mortality rate =
=1-2% in unselected pts with HCM

87

Hypertrophic Cardiomyopathy (HCM)

- Genetics: Autosomal dominant with variable penetrance
 - 11 mutant genes, > 500 mutations
- Variable manifestations
 - ==> asymmetric ventricular hypertrophy
 - Most pronounced in anterior ventricular septum
 - Increase occurs most commonly during periods of growth (ie. adolescence)
- Presentation:
 - May be asymptomatic
 - Chest pain
 - Symptoms of LVOT obstruction (SOB, DOE, syncope)
 - Sudden death

Most common cause of sudden death in athletic endeavors!

88


Hypertrophic Cardiomyopathy (HCM)

- PE: murmur noted in 30-40% only
 - Increases with Valsalva
- Chest x-ray: heart with normal size
- EKG: most are abnormal!!!!
 - 1) Large amplitude QRS complex ==> **Most common** (c/w LVH)
 - 2) Deep, narrow Q waves in: ==> **Most specific**
 - Inferior leads (II, III, AVF) and/or
 - Lateral leads (I, aVL, V5-6)
 - 3) ST changes are common → **But non-specific**

89

HCM - LVH, Q Waves in I, aVL, V5-6


- 30 y/o male lightheaded, palpitations after running. 2 days later, running => SCD.



90

HCM - LVH, Q Waves in I, aVL, V5-6


- 29 y/o male 3rd ED visit for lightheaded, palpitations with exertion.



91

HCM - LVH, Q Waves in I, aVL, V5-6

- 34 y/o male with CP and lightheadedness after biking 1-2 hours.



Q waves are defined as 25% of the height of the ensuing R wave

Beck S et al. Ann Emerg Med. May 2017

92

Hypertrophic Cardiomyopathy (HCM)

- Treatment: often medical (B-blockers)
- Complications:
 - 10-40% develop atrial fibrillation
 - Increase incidence of WPW

93

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)


- Described in 1982 (*Marcus et al*)
- Progressive loss of R ventricle myocardium (***replaced with fibrofatty tissue → thinning AND.. Ventricular arrhythmias***)
- Autosomal dominant (*but incomplete penetrance*)
- Prevalence: 1/ 2000-5000 (Italy, Germany)
 - Veneto region: 20% of deaths in young people

94


Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

- Presentation: palpitations or effort-induced syncope
- When: 2nd – 4th decade of life.

95




96



Triad...

- T wave inversion V1– V4
- Low voltage limb leads

97



Triad...

- T wave inversion V1– V4
- Low voltage limb leads
- Terminal activation duration (TAD)* is prolonged (normal < 55msec)

*TAD – nadir of S wave to the end of depolarization

98

Syncope and EKG Findings

1st Degree A-V Block, Mobitz 1, Mobitz 2 and 3rd Degree A-V Block*

- SSS/Tachy-brady, conduction abnormalities (blocks)
- Atrial and ventricular tachycardias
- Wolff-Parkinson-White (WPW)
- Prolonged QTc/Long QT syndrome
- Brugada Syndrome
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

* Admit/Cardiology

99

Syncope: The Evaluation

- I. The History-

Step 1: Risk Factors

Step 2: The episode

Step 3: What are the meds?


Step 4: “How are you feeling”?

- II. The Physical Exam

- III. The EKG (and “sniper” diagnostics)

Decision Time: Admit or discharge?

100



101

The Bottom Line - and Where Do We Go From Here?

- 650 ED patients with syncope prospectively evaluated
- Results: 495 (76%) diagnosed in ED
 - Vasovagal syncope 234/650 (47%)
 - Hypotension 156/650 (32%)
 - Neuro/psychiatric 41/650 (8%)
 - Cardiac (AMI, PE, AS) 29/650 (6%)
 - Arrhythmia 26/650 (5%)
- 155(24%) unexplained syncope

Sarasin FP, et al. Heart 2002; 88: 363-67

102

Unexplained Syncope: Evaluation

In-patient

VS

Out-patient

Will a clinical decision rule (CDR) help?

Answer: Perhaps...risk stratify?

103

CDR's for Syncope

- SF Syncope Rule
- Boston
- OESIL - Italy
- EGSYS - Italy
- ROSE – Scotland
- STePs (2008)
- Syncope Risk score
- Canadian Syncope Risk score**

Predisposition to vasovagal symptoms Triggered by being in a warm crowded place, prolonged standing, fear, emotion, or pain	No 0	Yes -1
Heart disease history CAD, atrial fibrillation or flutter, CHF, valvular disease	No 0	Yes +1
sBP <90 or >180 mmHg On any reading	No 0	Yes +2
Elevated troponin >99th percentile of normal population	No 0	Yes +2
Abnormal QRS axis <-30° or >100°	No 0	Yes +1
QRS duration >130 ms	No 0	Yes +1
Corrected QT interval >480 ms	No 0	Yes +2
ED diagnosis Based on ED evaluation	Vasovagal syncope -2 Cardiac syncope +2 Neither 0	
0 points Canadian Syncope Risk Score	Low risk 1.9% risk of 30-day serious adverse event (death, arrhythmia, MI — full list in Evidence)	

104

Unexplained Syncope: Evaluation ACC/AHA 2017

- A. ECHO → ...if structural heart dz is suspected (Class IIa)
- B. EST → ...if associated with exertion (Class IIa)
- C. Non-invasive ECG monitoring → ...if you suspect arrhythmia (Class IIa)
- Holter, Event recorders
- Implantable loop recorders
- D. Tilt-table testing → ...useful for suspect vasovagal (Class IIa)
- E. Carotid artery studies →

105

Anderson KL, et al. Ann Emerg Med
October 2012; 60:478-484.

323 ED pts admitted to “observation unit”

267 had **“normal”** EKG

235 underwent ECHO

Result: # of abnormal ECHO studies=

0, Zero, Zip, nada, etc...

106

Unexplained Syncope: Evaluation ACC/AHA 2017

A. ECHO → ...if structural heart dz is suspected (Class IIa)

B. EST → ...if associated with exertion (Class IIa)

C. Non-invasive ECG monitoring

- Holter, Event recorders
- Implantable loop recorders

→ ...if you suspect
arrhythmia (Class IIa)

D. Tilt-table testing → ...useful for suspect vasovagal (Class IIa)

E. Carotid artery studies →

107



108

Unexplained Syncope: Evaluation ACC/AHA 2017

- A. ECHO → ...if structural heart dz is suspected (Class IIa)
- B. EST → ...if associated with exertion (Class IIa)
- C. Non-invasive ECG monitoring → ...if you suspect arrhythmia (Class IIa)
 - Holter, Event recorders
 - Implantable loop recorders
- D. Tilt-table testing → ...useful for suspect vasovagal (Class IIa)
- E. Carotid artery studies → No, no no!!! (Class III)

109

The Bottom Line - and Where Do We Go From Here?

- 650 ED patients with syncope prospectively evaluated
- Results: 495 (76%) diagnosed in ED
 - Vasovagal syncope 234/650 (47%)
 - Hypotension 156/650 (32%)
 - Neuro/psychiatric 41/650 (8%)
 - Cardiac (AMI, PE, AS) 29/650 (6%)
 - Arrhythmia 26/650 (5%)
- 155(24%) unexplained syncope

Sarasin FP, et al. Heart 2002; 88: 363-67

110

Reflex (Neurally Mediated) Syncope – Vasovagal Syncope – Most Common

- 20-40% of the population have an episode in lifetime^{1,2}
- Theory: Failure (abnormal) autonomic NS to maintain BP & HR
 - Starts with excessive peripheral pooling (500-800ml blood)
 - Subsequent paradoxical rise in vagal activity
 - Can be “situational” (eg. defecation, urination, cough)

¹Salari N, et al [Global Epidemiology](#) June 2024, 100136

²M Taidini, et al. *European Heart J* November 2023

111

Reflex (Neurally Mediated) Syncope – Vasovagal Syncope – Most Common

- 20-40% of the population have an episode in lifetime^{1,2}
- Theory: Failure (abnormal) autonomic NS to maintain BP & HR
 - Starts with excessive peripheral pooling
 - Subsequent paradoxical rise in vagal activity
 - Can be “situational” (eg. defecation, urination, cough)


35% of patients will have syncope recurrences

- not associated with increased mortality,
- + associated with injury and reduced quality of life

Raj SR, et al. JACC: Clinical Electrophysiology, 2022

112

Recurrent Vasovagal Syncope: Management



113

ARS Question 2:
Which One of the Following Does **NOT** Decrease
Recurrent Episodes of Vasovagal Syncope?

- A. Midodrine
- B. B-blockers
- C. SSRI
- D. Closed loop stimulation pacing


114

ARS Question 2: Which One of the Following Does NOT Decrease Recurrent Episodes of Vasovagal Syncope?

A. Midodrine

B. B-blockers

C. SSRI

D. Closed loop stimulation
pacing

Kaza N, et al. Open Heart 2024; 11: e002669



115

Recurrent Vasovagal Syncope: Medical Management

- Midodrine:** 2 RCT, placebo-controlled studies: 179 patients
Methods: 133 pts with aver. 6 syncope episodes in the prior year
(median age, 32 years; 73% female)

Results @ 1year:

(+) syncopal episode

Midodrine

28/66 (42%)

placebo


41/67 (61%)

 $RRR = 0.69$ (95% CI, 0.49 to 0.97; $P = 0.035$)**NNT= 5**Sheldon R, et al . Ann Intern Med 2021; 174: <https://doi.org/10.7326/M20-5>

116

Recurrent Vasovagal Syncope: Medical Management

- **Midodrine:** 2 RCT, placebo-controlled studies: 179 patients
- **SSRI/SNRI:** 3 RCT, placebo-controlled studies: 204 patients
Paroxetine and fluoxetine




13% Vs. 37%; NNT= 4


Raj P et al. Clinical Autonomic Research (2023) 33:811–819

117

Recurrent Vasovagal Syncope: When Medical Management Fails....




Sensor in right atrium identifies reduced right ventricular filling, triggering the CLS algorithm → ...increase the pacing rate



118


Recurrent Vasovagal Syncope: When Medical Management Fails....



4 RCT trials: 345 patients¹

¹Kaza N, et al. Open Heart 2024; 11: e002669

²Brignole M et al. European Heart Journal, 2021; 42: 508–516



2

119


Last Word on Vasovagal Syncope: In the Office... Be Prepared

- At risk: young > old, women > men (1.5x)
Note: average of age of 1st episode = 14
- Painful procedures
 - blood draws
 - Vaccination
 - Tdap, meningococcal, **HPV**

120

Watch Out for HPV Vaccine Syncope

FIGURE. Number of postvaccination syncope* episodes reported to the Vaccine Adverse Event Reporting System, by month and year of report — United States, January 1, 2004–July 31, 2007



* Includes persons aged ≥ 5 years who had syncope onset after vaccination on the same date.

† Meningococcal conjugate vaccine.

‡ Date on which the Advisory Committee on Immunization Practices decided to add this newly licensed adolescent vaccine to the Vaccines for Children Program.

§ Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.

** Quadrivalent human papillomavirus recombinant vaccine. HPV is licensed only for females.

121

Syncope

- Definition - *very useful*
- Pathophysiology - *very useful*
- H & P elements - *that are useful*
- Tests/
Clinical Policies - *use EKG + "sniper diagnostics"*
- EKG's - *that are worrisome!*
- The outpatient evaluation

122

*Thank You For Your Time and
Consideration!!*

Post lecture ARS questions.....

123

ARS Question 1:

**ACEP (2007) and AHA/ACC (2017) Policies States Which
of the Following Tests Should Be Performed in All
Patients with Syncope?**

- A. EKG
- B. EKG + CBC
- C. EKG + CBC + troponin
- D. EKG + CBC + troponin + head CT
- E. Head CT

124

ARS Question 2:

Which One of the Following Does NOT Decrease Recurrent Episodes of Vasovagal Syncope?

- A. Midodrine
- B. B-blockers
- C. SSRI
- D. Closed loop stimulation pacing



125

Supplemental Slides

126

The Role of Echo in the Evaluation of Syncope: A Prospective Study

Sarasin FP, et al. Heart 2002; 88: 363-67.

- 155 patients with unexplained syncope
 - All get ECHO
- Result: # of abnormal ECHO studies=

0, Zero, Zip, nada, etc...

127

Echocardiography in the Evaluation of Patients with Syncope

Recchia D, et al. J Gen Intern Med 1995; 10: 649

- 128 patients **admitted patients** with unexplained syncope
 - All get ECHO
- Result: # of abnormal ECHO studies=

0, Zero, Zip, nada, etc...

128

Holter Monitoring for Syncope: Diagnostic Yield in Different Patient Groups

Kuhne M, et al. QJ Med 2007; 100: 771-7.

• Age group (yrs)	# pts. without structural HD	Diagnostic Holter (%)
<40	39	0 (0%)
40 - 50	29	0 (0%)
51 - 60	53	2 (4%)
61 - 70	59	2 (3%)
71 - 80	153	12 (8%)
81 - 90	100	7 (7%)
> 90	18	5 (28%)

129

“Old” ACC/AHA 2006 Statement.. On Tilt-table Testing

- **Sensitivity 26%-80%**
- **Specificity is approximately 90%.**

“In patients with a negative evaluation, ie, no evidence of ischemia and a structurally normal heart, the pretest probability that the diagnosis is neurocardiogenic syncope is high, so head-up tilt-table testing contributes little to establishing the diagnosis.”

In other words... in a patient with a normal evaluation who has a negative tilt table test, the most likely diagnosis is still neurocardiogenic syncope

130

Recurrent Vasovagal Syncope: Management

■ Physical counterpressure maneuvers

■ PC Trial: 223 pts - decreased syncope episodes (2006)

■ Increased fluid and salt intake

■ Midodrine 5mg tid

These do NOT work...

-Beta-blockers (see POST trial, Circulation, 2006)

-fludrocortisone (POST 2 trial, J Am Coll Cardiol. 2016)

-pacemaker (*providing not prolonged asystole*)
(see Vasovagal Pacemaker Study II, JAMA, 2003)

131

Note on Pacemakers:

1) Useful in (Spontaneous) Brady/Asystole

- Methods: 77 pts with either:
 - >3 sec asystole + syncope or
 - > 6 sec without syncope
 - All receive pacer, randomly assigned to:
- Results:

	<u>Pacer “on”</u>	<u>Pacer “off”</u>
syncope in 2 yrs	25%	57%


ISSUE-3 trial, Circulation, published ahead of print, 5/7/12

132

Note on Pacemakers:

- 1) Useful in (Spontaneous) Brady/Asystole
- 2) Not Useful in Vasovagal Syncope

Figure 2. Time to First Recurrence of Syncope



*VPS II trial
JAMA 2003
100 patients*

Relative risk reduction of 30.2% (95% confidence interval, -33.2% to 63.4%; log-rank $P = .14$).

133

Excellent Reference



Europace (2013) **15**, 1389–1406
doi:10.1093/europace/eut272


HRS/EHRA/APHRS CONSENSUS STATEMENT

Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes

Silvia G. Priori, (HRS Chairperson)¹, Arthur A. Wilde, (EHRA Chairperson)², Minoru Horie, (APHRS Chairperson)³, Yongkeun Cho, (APHRS Chairperson)⁴, Elijah R. Behr⁵, Charles Berul⁶, Nico Blom^{7*}, Josep Brugada⁸, Chern-En Chiang⁹, Heikki Huikuri¹⁰, Prince Kannankeril^{11‡}, Andrew Krahn¹², Antoine Leenhardt¹³, Arthur Moss¹⁴, Peter J. Schwartz¹⁵, Wataru Shimizu¹⁶, Gordon Tomaselli^{17†}, Cynthia Tracy¹⁸

134


47y/o Male Unresponsive, Found with Empty Bottles of Amitriptyline and Cyclobenzaprine



Kim HS, et al Ann Emerg Med, May 2017

135

47y/o Male Unresponsive, Found with Empty Bottles of Amitriptyline and Cyclobenzaprine




A. Before treatment

B. After Na bicarb

Kim HS, et al Ann Emerg Med, May 2017


136

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)



- **“Epsilon Wave”** (*small-amplitude distinct potentials between the end of the of the QRS and the beginning of the T wave*) is late manifestation

137



138

Antipsychotics and QTc

